Capula Management Ltd Invests $310,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Capula Management Ltd acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 8,574 shares of the specialty pharmaceutical company's stock, valued at approximately $310,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $52,000. Headlands Technologies LLC raised its stake in shares of Supernus Pharmaceuticals by 203.0% in the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 1,015 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $72,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $92,000.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the business's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,104 shares of company stock worth $440,263. Insiders own 9.30% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SUPN shares. Cantor Fitzgerald restated a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com downgraded Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday.

Supernus Pharmaceuticals Trading Up 1.9 %

Shares of SUPN traded up $0.60 on Friday, reaching $31.67. 407,129 shares of the company's stock were exchanged, compared to its average volume of 492,505. The business has a 50 day moving average price of $33.52 and a two-hundred day moving average price of $35.07. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a market capitalization of $1.77 billion, a P/E ratio of 29.60 and a beta of 0.90.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.